Incidence of biosimilars on the total marketed products in Italy in 2019, by molecule

The graph displays the incidence of biosimilar drugs consumption on the total marketed products in Italy in 2019, by molecule. According to data, Filgrastim, Rittuximab, and Epoetin were the molecules for which the incidence of biosimilar variations on the total marketed products was higher. More specifically, the biosimilar drugs produced from Filgrastim accounted for 95.87 percent of the total sales of this molecule, while all the other products represented 4.13 percent of the market.

Incidence of biosimilar drugs consumption on the total marketed products in Italy 2019, by molecule

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until October 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

May 2020

Region

Italy

Survey time period

2019

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Generics and biosimilars in Italy"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.